A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma

Acta Oncologica

Volumn 42, Issue 5-6, 2003, Pages 605-619

  Gustavsson, Anita ^a   Osterman, Birgitta ^b   Cavallin Ståhl, Eva ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CHEMOTHERAPY; DISEASES; RADIOTHERAPY; TOXICITY; TUMORS;

NEUROTOXICITY;

ONCOLOGY;

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 131; PREDNISONE; RADIOISOTOPE; RITUXIMAB; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; GASTROINTESTINAL CARCINOMA; HEAD AND NECK CARCINOMA; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NOSE CARCINOMA; PARANASAL SINUS CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SALIVARY GLAND CARCINOMA; SKIN LYMPHOMA; STOMACH LYMPHOMA; WALDEYER RING; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; FEMALE; HUMANS; LYMPHOMA, HIGH-GRADE; LYMPHOMA, LOW-GRADE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; SWEDEN; TREATMENT OUTCOME;

EID: 0141525384     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310014435     Document Type: Review

References (82)

1. National Board of Health and Welfare, Sweden. Cancer incidence in Sweden 2000. Stockholm: National Board of Health and Welfare, Centre for Epidemiology, The Cancer Registry, 2001.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92. (O1)
3. Harris NL, Jaffe ES, Diebold J, et al. Lymphoma classification - from controversy to consensus: the R.E.A.L. and WHO classification of lymphoid neoplasms. Ann Oncol 2000; 11: 3-10. (O1)
4. Hiddemann W, Longo DL, Coiffier B, et al. Lymphoma classification - the gap between biology and clinical management is closing. Blood 1996; 88: 4085-9. (O1)
5. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model of aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-94. (R1/2031)
6. Glick JH, Kim K, Earle J, et al. An ECOG randomized phase III trial of CHOP vs CHOP+radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1995; 14: 391. (Abstr.)
7. Shchepotin IB, Evans SRT, Shabahang M, et al. Primary non-Hodgkin's lymphoma of the stomach: three radical modalities of treatment in 75 patients. Ann Surg Oncol 1996; 3: 277-84.
8. Pendlebury S, El Awadi M, Ashley, et al. Radiotherapy results in early stage low grade nodal non-Hodgkin's lymphoma. Radiother Oncol 1995; 36: 167-71. (R3/40)
9. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282-90. (R2/177)
10. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al. Clinical stage 1 non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 69: 1088-93. (R1/451)
11. Kamath SS, Marcus RB, Jr, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 1999; 44: 563-8. (R2/285)
12. 0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol 1996; 7: 713-8. (P3/26)
13. Stuschke M, Hoederath A, Sack H, et al. Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas. Results of a prospective multicenter study. Cancer 1997; 80: 2273-84. (P2/100)
14. De Los Santos JF, Mendenhall NP, Lynch JW. Is comprehensive lymphatic irradiation for low-grade non-Hodgkin's lymphoma curative therapy? Long-term experience at a single institution. Int J Radiat Oncol Biol Phys 1997; 38: 3-8. (R3/21)
15. Kelsey SM, Newland AC, Vaughan Hudson G, Jelliffe AM. A British National Lymphoma Investigation randomized trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localized non-Hodgkin's lymphoma. Med Oncol 1994; 11: 19-25. (C3/148)
16. Denham JW, Denham E, Dear KB, Hudson GV. The follicular non-Hodgkin's lymphomas - I. The possibility of cure. Eur J Cancer 1996; 32A: 470-9. (C3/-)
17. Brandt L, Kimby E, Nygren P, et al. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol 2001; 40: 213-23.
18. Girinsky T, Guillot-Vals D, Koscielny S, et al. A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. Int J Radiat Oncol Biol Phys 2001; 51: 148-55. (R2/48)
19. Osterman B, Cavallin-Ståhl E, Hagberg H, et al. High-grade non-Hodgkin's lymphoma stage I. A retrospective study of treatment, outcome and prognostic factors in 213 patients. Acta Oncol 1996; 35: 171-7. (R1/213)
20. Fuller LM, Krasin MJ, Velasquez WS, et al. Significance of tumour size and radiation dose to local control in stage I-III large cell lymphoma treated with CHOP-bleo and radiation. Int J Radiat Oncol Biol Phys 1995; 31: 3-11. (P2/146)
21. van der Maazen RWM, Noordijk EM, Thomas J, et al. Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas. Radiother Oncol 1998; 49: 1-7. (R2/296)
22. Oguchi M, Ikeda H, Isobe K, et al. Tumour bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan lymphoma radiation therapy group. Int J Radiat Oncol Biol Phys 2000; 48: 161-8. (R1/787)
23. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-6. (C1/401)
24. Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001; 98: abstract 3024.
25. Munck JN, Dhermain F, Koscielny S, et al. Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non-Hodgkin's lymphomas: long-term results for 96 patients with tumours > 5 cm. Ann Oncol 1996; 7: 925-31. (P2/96)
26. Freilone R, Botto B, Vitolo U, et al. Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma. Ann Oncol 1996; 7: 919-24. (P2/84)
27. Kimby E, Brandt L, Nygren P, et al. A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol 2001; 40: 198-212.
28. Avilés A, Delgado S, Nambo M J, et al. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 1994; 30: 799-803. (C3/88)
29. Ferreri AJM, Dell'Oro S, Reni M, et al. Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas. Oncology 2000; 58: 219-26. (R2/94)
30. Richaud PM, Soubeyran P, Eghbali H, et al. Place of low dose total body irradiation in the treatment of localized follicular non-Hodgkin's lymphoma: results of a pilot study. Int J Radiat Oncol Biol Phys 1998; 40: 387-90. (P3/26)
31. Safwat A. The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: a new look at an old method. Radiother Oncol 2000; 56: 1-8. (L1)
32. Travis LB, Weeks J, Curtis RE, et al. Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 565-71. (R2/61)
33. Mahé M-A, Bourdin S, Le Pourhiet-Le Mevel A, et al. Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 735-8. (R3/34)
34. Apostolidis J, Gupta RK, Grenzelias D, et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527-36. (R1/99)
35. Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 15-21. (L1)
36. Aristei C, Tabilo A. Total-body irradiation in the conditioning regimens for autologous stem cell transplantation in lymphoproliferative diseases. Oncologist 1999; 4: 386-97. (L1)
37. Milligan DW, Ruiz de Elvira MC, Kolb HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol 1999; 106: 1020-6. (R1/4998)
38. Corn BW, Marcus SM, Topham A, et al. Will primary central nervous system lymphoma be the most frequent brain tumour diagnosed in the year 2000? Cancer 1997; 79: 2409-13. (O1)
39. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol 1999; 26: 346-56. (L1)
40. Krogh-Jensen M, D'Amore F, Jensen MK, et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumours in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO and the Danish Cancer Registry. Leuk Lymphoma 1995; 19: 223-33. (O1)
41. Laperriere NJ, Wong CS, Milosevic MF, et al. Accelerated radiation therapy for primary lymphoma of the brain. Radiother Oncol 1998; 47: 191-5. (P2/10)
42. Ferreri AJM, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11: 927-37. (L1)
43. Abrey LE, Yahalom J, DeAngelis LM. Treatment of primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144-50. (P2/52)
44. Goldkuhl C, Ekman T, Wiklund T, Telhaug R for the Nordic Lymphoma Group. Age-adjusted chemotherapy for primary central-nervous lymphoma - A pilot study. Acta Oncol 2002; 41: 29-35.
45. Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cancer 2000; 89: 1359-70. (C3/53)
46. Reni M, Ferreri AJM, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8: 227-34. (L1/676)
47. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-63. (P3/31)
48. O'Brien P, Roos D, Pratt G, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-26. (P2/46)
49. Corry J, Smith JG, Wirth A, et al. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998; 41: 615-20. (R3/62)
50. Laperriere NJ, Cerezo L, Milosevic MF, et al. Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 1997; 43: 247-52. (R3/49)
51. DeAngelis LM. Primary central nervous system lymphoma: an update. Educational book of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12-15, San Francisco; 2001. p. 277-80. (L1)[G3]
52. Gospodarowicz MK, Zucca E. Primary testis lymphoma: presentation, treatment, patterns of failure, and outcomes. Educational book of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12-15, San Francisco; 2001 p. 281-5. (L1)[G4]
53. Zucca E, Conconi A, Mughal T, et al. Patterns of survival in primary diffuse large-cell B-cell lymphoma (DLCL) of the testis. An international survey of 373 patients. Blood 2000; 96: 334a. (Abstr.)
54. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000; 46: 1093-103. (L1)
55. The Non-Hodgkin's Lymphoma Classification Project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-18. (O1)
56. Isaacson PG. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type. Educational Book of the 37th Annual Meeting of the American Society of Clinical Oncology; May 12-15, San Francisco; 2001. p. 273-6. (L1)
57. Rohatiner A, on behalf of d'Amore F, Coiffier B, Crowther D, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400. (O1)
58. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. Ann Oncol 1997; 8: 727-37. (L1)
59. Isaacson G. Gastric MALT lymphoma: from concept to cure. Ann Oncol 1999; 10: 637-45. (O1)
60. Liu H, Ruskone-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40. (O1/22)
61. Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89: 1350-5. (P1/50)
62. de Jong D, Aleman BMP, Taal BG, Boot H. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Ann Oncol 1999; 10: 275-80. (O1)
63. Yahalom J, Schechter JNR, Gonzales M, Portlock CS. Effective treatment of MALT lymphoma of the stomach with radiation alone. Ann Oncol 1999; 10: 135. (Abstr.)
64. Willich NA, Reinartz G, Horst EJ, et al. Operative and conservative management primary gastric lymphoma: interim results of a German multicenter study. Int J Radiat Oncol Biol Phys 2000; 46: 895-901. (P1/169)
65. Haim N, Leviov M, Ben-Arieh Y, et al. Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy. Leuk Lymphoma 1995; 17: 321-6. (P3/24)
66. Tondini C, Balzarotti M, Santoro A, et al. Initial chemotherapy for primary respectable large-cell lymphoma of the stomach. Ann Oncol 1997; 8: 497-9. (P3/17)
67. Fischbach W, Dragosics B, Kolve-Goebeler M-E, et al. for the German-Austrian gastrointestinal study group. Primary gastric B-cell lymphoma: results of a prospective multicenter study. Gastroenterology 2000; 119: 1191-202. (P1/236)
68. Ansell SM, Grant C S, Haberman TM. Primary thyroid lymphoma. Semin Oncol 1999; 26: 316-23. (L1)
69. Gospodarowicz MK, Sutcliffe SB. The extranodal lymphomas. Semin Radiat Oncol 1995; 5: 281-300. (L1)
70. Laing RW, Hoskin P, Vaughan Hudson B, et al. The significance of MALT histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol 1994; 6: 300-4. (R2/45)
71. Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023-33. (L1)
72. Avilés A, Delgado S, Ruiz H, et al. Treatment of non-Hodgkin's lymphoma of Waldeyer's ring: radiotherapy versus chemotherapy versus combined therapy. Oral Oncol Eur J Cancer 1996; 32B: 19-23. (C2/316)
73. Yuen A, Jacobs C. Lymphomas of the head and neck. Semin Oncol 1999; 26: 338-45. (L1)
74. Avilés A, Delgado S, Huerta-Guzman J. Marginal zone B cell lymphoma of the parotid glands: results of a randomized trial comparing radiotherapy to combined therapy. Oral Oncol Eur J Cancer 1996; 32B: 420-2. (C3/39)
75. Li YX, Coucke PA, Li J-Y, et al. Primary non-Hodgkin's lymphoma of the nasal cavity. Prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998; 83: 449-56. (R1/175)
76. Logsdon MD, Ha CS, Kavadi VS, et al. Lymphoma of the nasal cavity and paranasal sinuses. Improved outcome and altered prognostic factors with combined modality therapy. Cancer 1997; 80: 477-88. (R2/70)
77. Cheung MMC, Chan JKC, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumour immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998; 16: 70-7. (R2/113)
78. Liang R, Todd D, Chan TK, et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 1995; 13: 666-70. (R2/100)
79. Corcoran MC, Eary J, Bernstein I, Press OW. Radioimmunotherapy strategies for non-Hodgkin's lymphomas. Ann Oncol 1997; 8: 133-8. (L1)
80. Press OW. Innovative new therapies for non-Hodgkin's lymphomas: monoclonal antibodies and immunoconjugates. Educational book of the 36th Annual Meeting of the American Society of Clinical Oncology; May 19-23, New Orleans; 2000. p. 328-37. (L1)[G5]
81. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270-8. (P2/29)
82. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-63. (C2/143)